One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: A retrospective study;Studio retrospettivo sull’efficacia a un anno della terapia medica con liraglutide e della chirurgia bariatrica nel trattamento del paziente con diabete di tipo 2 e obesità

Giornale Italiano di Diabetologia e Metabolismo

Volumn 34, Issue 2, 2014, Pages 58-63

  Vitagliano, G ^a   Nosso, G ^a   Cotugno, M ^a   Saldalamacchia, G ^a   Lupoli, R ^a   Griffo, E ^a   Angrisani, L ^b   Riccardi, G ^a   Capaldo, Brunella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Ospedale S Giovanni Bosco   (Italy)

Author keywords

Liraglutide; Obesity; Type 2 diabetes mellitus; Weight loss

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C; LIRAGLUTIDE;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; DIABETIC OBESITY; DRUG USE; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84907471769     PISSN: 15936104     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248-56.
2. Polymeris A, Karoutsou E, Michaiakis K. The impact of bariatric surgery procedures on type 2 diabetes, hyperlipidemia and hypertension. Hellenic J Cardiol 2013;54:212-7.
3. Druker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2928-40.
4. Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H et al. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med 2013;52:1029-34.
5. Van der Klauw MM, Wolffenbutte BH. The combination of insulin and GlP-1 analogues in the treatment of type 2 diabetes. Neth J Med 2012;70:436-43.
6. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient – 2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity 2013;21(suppl. 1):S1-27.
7. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE et al. How do we define cure of diabetes? Diabetes Care 2009;32:2133-5.
8. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76.
9. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-85.
10. Ikramuddin S, Korner J, Lee WJ, Connet JE, Inabnet III WB, Billington CJ et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA 2013;309:2240-9.
11. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f5934.
12. Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther 2013;4:147-51.
13. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-6.
14. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin a1c targets. a guidance statement from the American college of physicians. Ann Intern Med 2007;147:417-22.
15. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 2012;98:386-95.
16. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2012.
17. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-75.
18. Griffo E, Nosso G, Lupoli R, Cotugno M, Saldalamacchia G, Vitolo G et al. Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients. Obes Surg 2014;24:765-70.
19. Patti ME, Goldfine AB. Hypoglycaemia following gastric bypass surgery-diabetes remission in the extreme? Diabetologia 2010; 53:2276-9.